Obulytix is a biotechnology company from Ghent University and KU Leuven, focusing on developing phage lysin-based antibiotics to combat antimicrobial resistance. Their proprietary platform adapts the hit-to-lead process from drug discovery to phage lysin-based antibiotics, utilizing artificial intelligence to enhance efficiency and throughput.
One Ecosystem | Three Platforms
